Publisher
Springer Science and Business Media LLC
Subject
Psychiatry and Mental health,Clinical Neurology,Neurology,General Medicine
Reference26 articles.
1. Amsterdam JG van, Laar M van, Brunt TM, Brink W van den (2012) Risk assessment of gamma-hydroxybutyric acid (GHB) in the Netherlands. Regul Toxicol Pharmacol 63(1):55–63.
https://doi.org/10.1016/j.yrtph.2012.03.005
(Epub 2012 Mar 14)
2. Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, Watson DE (2004) Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 28:625–630
3. Carai MA, Colobo G, Reali R, Serra S, Mocci I, Castelli MP, Cignarella G, Gessa GL (2002) Central effects of 1.4-butanediol are mediated by GABA(B) receptorsvia its conversion into gamma-hydroxybutyric acid. Eur J Pharmacol 441(3):157–163
4. Corkery JM, Loi B, Claridge H, Goodair C, Corazza O, Elliott S, Schifano F (2015) Gamma hydroxybutyrate (GHB), gamma butyrolactone (GBL) and 1,4-butanediol (1,4-BD; BDO): A literature review with a focus on UK fatalities related to non-medical use. Neurosci Biobehav Rev 53:52–78.
https://doi.org/10.1016/j.neubiorev.2015.03.012
(Epub 2015 Apr 3)
5. Europäische Beobachtungsstelle für Drogen und Drogensucht (EMCDDA). Europäischer Drogenbericht 2017.
http://www.emcdda.europa.eu/publications/edr/trends-developments/2016
. Zugegriffen: 9. März 2018
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献